der User Banani hat ihnen eine konstruktive Frage gestellt und damit einen idealen Einstieg in eine inhaltliche Diskussion zum Unternehmen geliefert, die ihnen ihrem ersten Beitrag zufolge hier fehlt. darauf folgen zwei arrogante und herablassende Antworten ihrerseits. wundern sie sich bitte nicht, wenn hier keiner mit ihnen kommuniziert. sie hatten es quasi in der eigenen Hand.
: territory exclusive distribution agreements
T2 Biosystems Announces Commercial Expansion Through Distributors in Norway, Finland and Türkiye
…We are committed to expanding our commercialization worldwide and these new distribution agreements provide access to important markets in Norway, Finland, and Türkiye,” said John Sperzel, Chairman and CEO of T2 Biosystems. “We believe these three countries represent significant growth potential for our culture-independent rapid diagnostics and look forward to building lasting relationships with our distributors as we work to improve the quality of care for those patients at risk of sepsis.”
: Fourth Quarter & Full Year 2021 Financial Results
Full Year 2021 and Recent Highlights
•Achieved full year 2021 total revenue of $28.1 million, including product revenue of $16.6 million, representing increases of 55% and 43%, respectively, compared to the prior year
•Achieved full year 2021 sepsis test panel revenue of $5.1 million, representing an increase of 46% compared to the prior year
•Achieved full year 2021 research and contribution revenue of $11.4 million, representing an increase of 77% compared to the prior year
•Executed contracts for 32 T2Dx® Instruments in 2021, including 17 instrument contracts during the fourth quarter
•Expanded international commercialization by entering into exclusive distributor agreements in Mexico, Singapore, South Korea, Taiwan, Norway, Finland, and Türkiye
•Strengthened leadership team by hiring industry veterans Aparna Ahuja MD as Chief Medical Officer, and Brett Giffin as Chief Commercial Officer, and significantly expanded sales, marketing, clinical and medical affairs teams
•Initiated U.S. clinical trials for the T2Resistance® Panel and T2Biothreat® Panel in December 2021, enabling potential filing of FDA submissions for both products during 2022
•Amended term loan agreement with CRG, extending both the interest-only period and the maturity date to December 31, 2023
"As we previously disclosed we are not in compliance with NASDAQ’s $1.00 listing requirement. We plan to regain compliance by executing on our operating plans and organically drive our share price to compliance and we currently have no plans for a reverse stock split."
Dann lasst uns mal hoffen, bin nur gespannt wie sie das schaffen wollen.
: T2 Biosystems Announces BARDA Exercise of
Contract Option 2B Valued at $4.4 Million
...is providing an additional $4.4 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems. The total potential BARDA funding if all contract options are exercised is $69.0 million.
The additional funding will be used to advance the U.S. clinical trials for the T2Biothreat® Panel and T2Resistance® Panel, and to advance the development of the Company’s comprehensive panel for the detection of bloodstream infections and antimicrobial resistance, and next-generation instrument.
T2Biothreat® Panel: a direct-from-blood test panel designed to run on the T2Dx Instrument and simultaneously detect six biothreat pathogens, including: Bacillus anthracis, Francisella tularensis, Burkholderia mallei, Burkholderia pseudomallei, Yersinia pestis, and Rickettsia prowazekii. T2Resistance® Panel: a direct-from-blood test panel designed to run on the T2Dx Instrument and simultaneously detect thirteen antibiotic resistance genes from both Gram-positive and Gram-negative bacterial pathogens, which are known to cause antibiotic-resistant infections. Comprehensive panel for the detection of bloodstream infections and antimicrobial resistance: a direct-from-blood test panel designed to run on our next-generation instrument and detect greater than 95% of all bloodstream infections caused by bacterial and Candida pathogens, as well as antibiotic resistance markers identified as threats by the Centers for Disease Control and Prevention, in a single test with a time to result of approximately 3 hours. Next-generation instrument: a fully automated, random-access, high-throughput instrument designed in parallel with the comprehensive panel for the detection of bloodstream infections and antimicrobial resistance from a single whole blood sample. "We are pleased to have initiated U.S. clinical trials for both the T2Biothreat Panel and T2Resistance Panel in December 2021, enabling potential filing of FDA submissions for both products during 2022,” stated John Sperzel, Chairman and CEO of T2 Biosystems. “The products being developed and advanced toward commercialization have the potential to transform the detection of sepsis-causing pathogens, reduce the threat of antimicrobial resistance, and protect the nation from biothreat pathogens.”
This project has been funded in whole or in part with federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, under contract number 75A50119C00053.